STOCK TITAN
  1. Home
  2. Sec-filings
  3. STOK
  4. [Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Stoke Therapeutics (STOK) Form 4: CMO disposes 5,501 shares via 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Stoke Therapeutics Chief Medical Officer Barry Ticho sold 5,501 shares of STOK common stock on 09/02/2025 under a Rule 10b5-1 trading plan adopted on 12/11/2024. The reported weighted-average sale price was $19.8737 per share, with individual trade prices ranging from $19.54 to $20.34 per share. After the reported sales, the reporting person beneficially owned 18,469 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Positive

  • Transaction executed under a Rule 10b5-1 trading plan, indicating the sale was pre-planned
  • Filing discloses weighted-average price and full price range ($19.54 to $20.34), improving transparency
  • Post-transaction beneficial ownership disclosed (18,469 shares)

Negative

  • Insider disposition of 5,501 shares is a reduction in insider equity exposure

Insights

TL;DR: Insider sold a modest stake under a pre-established 10b5-1 plan; transaction appears orderly and planned.

The sale of 5,501 shares represents a disposition executed pursuant to a Rule 10b5-1 plan, which usually indicates pre-planned, non-discretionary selling rather than opportunistic insider timing. The filing discloses a weighted-average price of $19.8737 and a post-transaction beneficial ownership of 18,469 shares, allowing investors to quantify the remaining insider exposure. No derivatives or other transactions are reported.

TL;DR: Filing shows compliance with disclosure rules and use of an affirmative defense trading plan.

The Form 4 explicitly states the transaction was executed under a Rule 10b5-1 plan adopted on 12/11/2024, which provides the reporting person an affirmative defense against insider trading claims if conditions are met. The explanation includes price ranges and an offer to provide detailed trade-level data on request, which improves transparency. The signature by an attorney-in-fact is properly noted.

Insider Ticho Barry
Role CHIEF MEDICAL OFFICER
Sold 5,501 shs ($109K)
Type Security Shares Price Value
Sale Common Stock 5,501 $19.8737 $109K
Holdings After Transaction: Common Stock — 18,469 shares (Direct)
Footnotes (1)
  1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $20.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ticho Barry
(Last) (First) (Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
(Street)
BEDFORD MA 01730
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF MEDICAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/02/2025 S(1) 5,501 D $19.8737(2) 18,469 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $20.34 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Jonathan Allan, Attorney-in-Fact 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the Stoke Therapeutics (STOK) Form 4 filing disclose about insider activity?

The Form 4 shows Chief Medical Officer Barry Ticho sold 5,501 shares on 09/02/2025 under a Rule 10b5-1 plan, at a weighted-average price of $19.8737, leaving 18,469 shares beneficially owned.

Was the sale by the STOK reporting person part of a planned trading program?

Yes. The filing states the trades were executed pursuant to a Rule 10b5-1 trading plan adopted on 12/11/2024.

What price range was disclosed for the STOK shares sold in the Form 4?

The filing reports the sale occurred in multiple transactions at prices ranging from $19.54 to $20.34 per share.

How many STOK shares does the reporting person own after the reported transaction?

After the reported sales, the reporting person beneficially owns 18,469 shares.

Who signed the Form 4 for the reporting person?

The Form 4 was signed by Jonathan Allan, Attorney-in-Fact on 09/03/2025.